The Latest Breaking News from Novavax

Israel's Ministry of Health has agreed to purchase Novavax Inc's (NASDAQ: NVAX) protein-based COVID-19 vaccine candidate, NVX-CoV2373.

Novavax Inc. (NASDAQ: NVAX) shares lost ground Monday fell below support in a pennant pattern. The stock has also seen a strong drop in its Relative Strength Index. Novavax was down 6.12% at $79.47 at the close Monday.

Australia’s government is hoping the protein-based vaccine – approved by the TGA – will sway the hesitant to get the jab

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Thursday after Australia’s national drug regulator granted approval for the company's COVID-19 vaccine. The stock is trading below what traders call a pennant pattern and is showing uncertainty in where it could head next.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Novavax Inc (NASDAQ: NVAX) said Wednesday that Australia’s national drugs regulator has granted approval for its COVID-19 vaccine.

You might be wondering, why do we need another vaccine at all when most of us are fully vaccinated and some have received a booster? Here's what you need to know.

Novavax's COVID-19 vaccine has become the fifth coronavirus vaccine approved for use in Australia

The national drug regulator has approved the Novavax vaccine, as well as two oral treatments for vulnerable patients with COVID-19.